Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting (NYSE MKT LLC: DXR)

New York, NY, March 09, 2018 -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, exhibited at the 2018 Society for Critical Care Medicine Annual Meeting from February 25-28 in San Antonio, Texas where research was presented highlighting the positive clinical benefits of the use of Daxor’s BVA-100 blood volume system for critical care.

On February 26 Dr. Stephanie Yan of Queen’s Medical Center, Honolulu, Hawaii, presented a research study entitled Capillary Albumin Transudation Rate and Outcome in Critically Ill Subjects.. Dr Yan stated in her unique study utilizing the BVA-100 device both that “persistently elevated albumin transudation rate is associated with higher mortality” and “albumin transudation rate, as a point of care assay, is an early clinical tool used to guide treatment and measure response to interventions.” The Daxor BVA-100 is the only clinically available test that provides an albumin transudation diagnostic and the opportunity to intervene early for patients in the ICU setting.

On February 27 Dr. Colin Doyle also of Queen’s Medical Center, Honolulu, Hawaii presented a separate research study entitled Feasibility of Blood Volume Analysis-directed Diuresis in Subjects with Shock Requiring Vasopressors. Dr. Doyle stated that blood volume analysis guided diuresis of patients on vasopressors using the BVA-100 system is “feasible and associated with improvements in both vasopressor requirement and pulmonary function” and the practice has “no clear association with worsened renal function.”  Reduction in vasopressor use and improvement in pulmonary function are goals for optimal outcomes for ICU patient care.

Michael Feldschuh, CEO of Daxor said, “We are pleased to see yet another independent piece of clinical evidence validating the significant benefit of the BVA-100 to improve outcomes and resource use in the ICU.  We continue to emphasize the clinical as well as economic benefits of optimizing care in the ICU through fluid management guided by our direct and highly accurate volume measurement technology.”

Daxor will also exhibit at the 2018 Annual Meeting of the American College of Cardiology March 10-12 at the Orlando Convention Center in Orlando, Florida. The company will be located at booth number 1438 in the main exhibition hall and will engage attendees with physician education specialists as well as coordinate with researchers who are active in blood volume related cardiology research.

Soren Thompson, VP of business development for Daxor stated, “The ACC meeting is an excellent opportunity to educate more hospitals and cardiologists about the significant benefits of the BVA-100 for heart failure readmissions, mortality and cost of care. Better outcomes for patients and economic benefits for our partner hospitals are achievable when precision blood volume analysis is implemented as part of the standard of care. This meeting is one of our primary opportunities for bringing attention to cutting edge research as well as the successes of our current hospital clients, and for pushing forward collaborations that will lead to the next breakthroughs in cardiovascular patient care.”

New research will be presented by Dr. Wayne Miller of the Mayo Clinic and Dr. John Strobeck formerly of Valley Hospital entitled Propensity Score Matched-Controlled Study of Impact of Blood Volume Quantification on Decongestion Strategy, Readmission Rates and Mortality in Patients Hospitalized For Heart Failure in poster form from 10:00am to 10:45am in Poster Hall A/B.

Contact Information:

Daxor Corporation:  Soren Thompson 212-330-8502 (Investor Relations) [email protected]